crossing96/oncoscreening huggingface dataset:
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.	We report results of the final analysis of overall survival (OS) and patient-reported outcomes from the phase III KEYNOTE-585 (ClinicalTrials.gov identifier: NCT03221426) study. Participants with previously untreated, locally advanced, resectable gastric and gastroesophageal junction (G/GEJ) cancer were enrolled into the main (n = 804) and fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT; n = 203) cohorts, and randomly assigned 1:1 to neoadjuvant and adjuvant pembrolizumab plus chemotherapy or placebo plus chemotherapy. The primary end points were pathologic complete response (pathCR) by central review, event-free survival (EFS) by investigator, OS, and safety. Patient-reported outcomes was an exploratory end point. After a median follow-up of 59.9 months (range, 39-76), median OS was 71.8 versus 55.7 months (hazard ratio [HR], 0.86 [95% CI, 0.71 to 1.06]) with pembrolizumab plus chemotherapy versus placebo plus chemotherapy in the main cohort. The EFS HR was 0.81 (95% CI, 0.67 to 0.98). Grade ≥3 drug-related adverse event rates were 65% versus 63%. Perioperative pembrolizumab plus chemotherapy did not worsen health-related quality of life versus placebo. Pembrolizumab plus chemotherapy continued to show improved outcomes in pathCR and a trend toward longer EFS versus placebo in the main and main plus FLOT cohorts. Efficacy and safety outcomes with perioperative pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in participants with untreated, locally advanced resectable G/GEJ cancer were consistent with previous analyses.	esophagus
Pre- and Post-Operative Exercise and Nutrition Therapy in Patients with Esophageal Cancer Undergoing Esophagectomy: A Prospective Interventional Study.	<p>Introduction: This study aimed to evaluate safety and feasibility of perioperative exercise and nutrition therapy and to explore perioperative changes in skeletal muscle mass (SMM) in patients with esophageal cancer. METHODS: Patients scheduled for curative esophagectomy at two hospitals were enrolled. Exercise and nutrition therapy were performed for 3 weeks preoperatively and 4 weeks postoperatively. Outcomes included SMM, which was the sum of both mid-thigh cross-sectional area on computed tomography and physical function, assessed at T1 (intervention start), T2 (just before surgery), and T3 (1-month postoperatively). The SMM change rate between T1 and T3 was compared with the hypothesized value (-7.5%) from our previous study. RESULTS: Thirty-six patients underwent intervention and esophagectomy (intervention completion rate: 94.4%, no serious adverse events). The SMM increased by 4.9% for T1-T2 (p < 0.001) but decreased by 10.1% for T1-T3 (p < 0.001), suggesting that the primary outcome was not achieved. Physical function results were significantly better at T3 than at T1. Postoperative SMM loss was lower in patients who maintained postoperative caloric intake and physical activity than in those who could not (-8.3% vs. -15.4%, p = 0.011). CONCLUSIONS: Perioperative exercise and nutrition therapy were safe and feasible. An increase in preoperative SMM and postoperative physical function were observed, although SMM decreased after surgery. Further investigation is warranted to evaluate the efficacy of this intervention. </p>.	esophagus
Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report.	Immune checkpoint inhibitors (ICIs) have become an important part of malignant tumor therapy. However, some adverse reactions follow ICIs therapy. The incidence of immune-mediated colitis (IMC) has also increased. Here, the case of a 67-year-old male patient with stage IVB esophagogastric junction squamous cell carcinoma after chemotherapy, targeted therapy and immunotherapy is presented. This patient underwent treatment with six courses of protein-bound paclitaxel + cis-platinum+ sintilimab, followed by maintenance therapy with sintilimab alone. The patient developed intestinal obstruction, abdominal pain, hemorrhage of the lower digestive tract and other discomfort and was diagnosed with multiple jejunal ulcers via colonoscopy and pathological biopsy. The aims of presenting this case report are to improve clinicians' understanding of and ability to treat sintilimab-related adverse reactions and to more scientifically and rationally administer sintilimab for the treatment of malignant tumors.	esophagus
Plasma Lysophosphatidylcholine Levels Correlate with Prognosis and Immunotherapy Response in Squamous Cell Carcinoma.	Cancer is a systemic disease rather than a localized pathology and is characterized by widespread effects, including whole-body exhaustion and chronic inflammation. A thorough understanding of cancer pathophysiology requires a systemic approach that accounts for the complex interactions between cancer cells and host tissues. To explore these dynamics, we employed a comprehensive metabolomic analysis of plasma samples from patients with either esophageal or head and neck squamous cell carcinoma (SCC). Plasma samples from 149 patients were metabolically profiled and correlated with clinical data. Among the metabolites identified, lysophosphatidylcholine (LPC) emerged as the sole biomarker strongly correlated with prognosis. A significant reduction in plasma LPC levels was linked to poorer overall survival. Plasma LPC levels demonstrated minimal correlation with patient-specific factors, such as tumor size and general condition, but showed significant association with the response to immune checkpoint inhibitor therapy. Proteomic and cytokine analyses revealed that low plasma LPC levels reflected systemic chronic inflammation, characterized by high levels of inflammatory proteins, the cytokines interleukin-6 and tumor necrosis factor-α, and coagulation-related proteins. These findings indicate that plasma LPC levels may be used as reliable biomarkers for predicting prognosis and evaluating the efficacy of immunotherapy in patients with SCC.	esophagus
Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial.	BACKGROUND: Locally advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma faces high recurrence risks despite radical surgery. Perioperative chemotherapy (e.g., FLOT regimen) improves survival but has limited pathological complete response (pCR) rates and significant toxicity. Immunotherapy and anti-angiogenic agents show promise in advanced G/GEJ cancer. This trial evaluates fruquintinib (a VEGFR-1/2/3 inhibitor), sintilimab (PD-1 inhibitor), and SOX (oxaliplatin+S-1) as perioperative therapy for resectable locally advanced G/GEJ adenocarcinoma. METHODS: This prospective, single-arm, phase II trial (N = 25) enrolls treatment-naïve adults (18-75 years) with histologically confirmed, resectable cT3-4aN+M0 G/GEJ adenocarcinoma (AJCC 8th edition). Patients receive 3 cycles of neoadjuvant therapy:Fruquintinib:4 mg orally, days 1-14 (21-day cycle). S-1: 80-120 mg orally twice daily (based on BSA), days 1-14. Oxaliplatin: 130 mg/m² IV, day 1. Sintilimab: 200 mg IV, day 1.Radical gastrectomy with D2 lymphadenectomy follows 4-6 weeks post-neoadjuvant therapy. Adjuvant therapy (3 cycles of sintilimab for pCR patients; 3 cycles of preoperative regimen for non-pCR) starts 4-6 weeks post-surgery. Endpoints: Primary: pCR rate (ypT0/Tis ypN0 per CAP criteria). Secondary: R0 resection rate, major pathological response (MPR, ≤10% residual tumor), 2-year event-free survival (EFS), 2-year overall survival (OS), safety (NCI CTCAE v5.0). Exploratory: Biomarker analysis of tumor microenvironment. Statistical Analysis: Sample size (25 patients) was calculated using Fisher's exact test (one-sided α = 0.05, power = 80%), assuming pCR improvement from 5% (historical control) to 20%. Efficacy analyses use intention-to-treat (ITT) population; safety analyses include patients receiving ≥1 neoadjuvant dose. DISCUSSION: This is the first trial combining fruquintinib, sintilimab, and SOX in perioperative G/GEJ cancer. If successful, it may expand treatment options for locally advanced disease. Limitations include single-arm design and small sample size. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2400084194).	esophagus
[Esophageal metastasis from primary colon adenocarcinoma: presentation of an unusual clinical case].	Colorectal cancer is one of the tumors with the highest incidence and mortality worldwide. Despite being considered a preventable pathology due to the modifiable risk factors and the appropriate use of screening strategies, there are currently still important barriers with respect to access to health services and adoption of the screening tests, which is reflected in a non-negligible percentage of patients with the presence of metastasis or unresectable disease at the time of diagnosis. The most frequent sites of metastasis in colorectal cancer are widely known, however, these patients may present metastatic lesions to unusual sites that have not been frequently reported in the literature. We present the unusual case of a patient with colon cancer with metastasis to the esophagus.	esophagus
Circulating tumor DNA as a biomarker for progression and survival in esophageal cancer after neoadjuvant therapy and esophagectomy: a systematic review and meta-analysis.	BACKGROUND: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for monitoring treatment response and predicting outcomes in cancer. This meta-analysis aimed to evaluate the prognostic value of ctDNA in predicting survival outcomes and pathologic complete response (pCR) in esophageal cancer (EC) patients undergoing neoadjuvant therapy (NAT). METHODS: A systematic search of PubMed, Web of Science, and Embase was conducted between August and September 2024. Observational studies and randomized clinical trials were included if they reported associations between ctDNA detection and progression-free survival (PFS), overall survival (OS), or pCR. Fixed-effects models were used to pool hazard ratios (HRs) and odds ratios (ORs). Heterogeneity was quantified using I2 statistics, and publication bias was assessed via funnel plots and Egger's test. RESULTS: Among 71 studies screened, 10 met the inclusion criteria ( n = 334 patients). Baseline ctDNA detection was not significantly associated with PFS, OS, or pCR ( P > 0.05). However, ctDNA detection post-NAT was significantly associated with worse PFS (HR 3.81; 95% CI: 2.19-6.64), OS (HR 3.00; 95% CI: 1.64-5.50), and lower odds of pCR (OR 0.26; 95% CI: 0.09-0.73). Similarly, ctDNA detection post-surgery predicted worse PFS (HR 4.17; 95% CI: 2.17-8.04) and OS (HR 4.00; 95% CI: 1.90-8.42). CONCLUSION: ctDNA detection following NAT and surgery is a strong predictor of poor survival outcomes and lower pCR rates in EC. These findings underscore ctDNA's potential as a biomarker for risk stratification and personalized treatment planning in EC patients. Further standardization of ctDNA detection methods is essential to optimize its clinical utility.	esophagus
Amorphous-Crystalline Synergy in CoSe(2)/CoS(2) Heterostructures: High-Performance SERS Substrates for Esophageal Tumor Cell Discrimination.	Although surface-enhanced Raman scattering (SERS) spectroscopy is applied in biomedicine deeply, the design of new substrates for wider detection is still in demand. Crystalline-amorphous CoSe(2)/CoS(2) heterojunction is synthesized, with high SERS performance and stability, composed of orthorhombic (o-CoSe(2)) and amorphous CoS(2) (a-CoS(2)). By adjusting feed ratio, the proportion of a-CoS(2) to o-CoSe(2) is regulated, where CoSe(2)/CoS(2)-S50 with a 1:1 ratio demonstrates the best SERS performance due to the balance of two components. It is confirmed through experimental and simulation methods that o-CoSe(2) and a-CoS(2) have unique contribution, respectively: a-CoS(2) has rich vacancies and a higher density of active sites, while o-CoSe(2) further enriches vacancies, enhances electron delocalization and charge transfer (CT) capabilities, and reduces bandgap. Besides, CoSe(2)/CoS(2)-S50 achieves not only SERS detection of two common esophageal tumor cells (KYSE and TE) and healthy oral epithelial cells (het-1A), but also the discrimination with high sensitivity, specificity, and accuracy via machine learning (ML) analysis.	esophagus
Efficacy and Safety of Neoadjuvant Chemotherapy with or without Immune Checkpoint Inhibitors for Resectable Esophageal Squamous Cell Carcinoma: a Meta-analysis of Randomized Controlled Trials.	BACKGROUND: Recently, there has been significant attention focused on neoadjuvant immune checkpoint inhibitors combined with chemotherapy (NICT) for the treatment of resectable esophageal squamous cell carcinoma (ESCC). In order to assess the efficacy and safety of this innovative combination in relation to traditional neoadjuvant chemotherapy (NCT), we performed a systematic meta-analysis of randomized controlled trials (RCTs). METHODS: A comprehensive review of the literature was performed across Embase, Cochrane Library, Web of Science, and PubMed, covering the period from their inception to May 2, 2025, to identify appropriate RCTs. The primary outcomes included pathological complete response (pCR) and major pathological response (MPR), R0 resection rate, event-free survival (EFS), and overall survival (OS). The adverse events (AEs) was identified as the secondary outcome. RESULTS: A total of five RCTs involving 755 patients were included for the final analysis. The result showed that compared with the NCT group, the NICT group for resectable ESCC significantly improved pCR (RR = 2.51; 95% CI: 1.64-3.84; P < 0.01) and MPR (RR = 1.83; 95% CI: 1.16-2.88; P = 0.01). The pooled rates of pMR and MPR in the NICT group were significantly higher compared to the NCT group, with values of 23.2% versus 7.7% and 42.8% versus 25.8%. The R0 resection rate was comparable between the two groups (RR = 1.00; 95% CI: 0.99-1.02; P = 0.63) with pooled rates observed to be 100% for the NICT group and 98.2% for the NCT group. However, only one phase III RCT reported survival outcomes that demonstrated improved 1-year EFS rate (HR = 0.62, 95% CI: 0.39-1.00, P = 0.05) and 1-year OS rates (HR = 0.48, 95% CI: 0.24-0.97, P = 0.037) in the NICT group. Nevertheless, the analysis revealed no statistically significant differences in grade ≥ 3 TRAEs across the treatment strategies (RR = 1.03; 95% CI: 0.80-1.32; P = 0.82), with pooled rates recorded at 34.4% for the NICT group and 33.1% for the NCT group. The pooled rates were observed to be 24.7% for all grade immune-related adverse events (irAEs) and 3.1% for grade ≥ 3 irAEs. CONCLUSIONS: Combining ICIs with chemotherapy as a neoadjuvant approach shows significant therapeutic promise in treating resectable ESCC, exhibiting favorable efficacy and acceptable safety profiles in the Chinese population. Nonetheless, more additional large-scale phase III RCTs are warranted for further validation of these preliminary outcomes.	esophagus
Case Report: The huge esophageal displacement: a case of dramatic esophageal interfraction motion during neoadjuvant chemotherapy and immunotherapy.	BACKGROUND: The average movement of esophagus is about 0.15 to 0.4 cm radially and 0.3 to 0.9 cm in the superior-inferior during radiotherapy. Little study has reported giant shift of esophagus during neoadjuvant chemotherapy and immunotherapy. CASE PRESENTATION: Here we presented a case of a 72-year-old male patient diagnosed with advanced lower thoracic esophageal squamous cell cancer, clinical T2N2M1, stage IVB (pulmonary metastasis). The esophagus moved about 4.2 cm radially from the right to the left of the aorta after 2 cycles of chemotherapy and immunotherapy. CONCLUSION: All in all, we treated a patient with advanced lower thoracic esophageal squamous cell cancer that occurred a dramatic radial escape of about 4.2 cm after 2 cycles of chemotherapy and immunotherapy.	esophagus
Variables related to locoregional and distant recurrence in esophageal cancer.	BACKGROUND: Esophageal cancer remains one of the most aggressive malignancies of the gastrointestinal tract, with high rates of recurrence and mortality despite curative-intent surgery and adjuvant therapies. Identifying factors associated with recurrence is crucial for improving outcomes and guiding personalized treatment. AIMS: The aim of this study was to evaluate pretreatment and treatment-related variables associated with recurrence in patients with esophageal cancer undergoing surgical resection. METHODS: This retrospective study analyzed data from patients with stage I-III esophageal carcinoma who underwent esophagectomy between 2000 and 2025, using the Fundação Oncocentro de São Paulo (FOSP) database. Clinical, histological, and treatment-related variables were evaluated. Disease-free survival and recurrence patterns were assessed using Cox proportional hazards models and Fine-Gray subdistribution hazard models. RESULTS: A total of 2,057 patients were included, with a mean follow-up of 36.5 months (±44.8). In the multivariate analysis, advanced tumor stage (stage II: HR 1.68, 95%CI 1.21-2.33; stage III: HR 3.23, 95%CI 2.29-4.56; both p<0.01), location (middle esophagus: HR 1.31, 95%CI 1.11-1.54; p=0.001; upper esophagus: HR 1.54, 95%CI 1.21-1.96; p<0.001), and histological subtype (rare histologies: HR 2.17, 95%CI 1.35-3.49; p=0.001) were associated with worse disease-free survival. Multimodal therapy improved disease-free survival (HR 0.40, 95%CI 0.24-0.66) in stage III tumors. Squamous cell carcinoma was independently associated with locoregional recurrence (SHR 1.52, 95%CI 1.05-2.20; p=0.027). For distant recurrence, squamous cell carcinoma showed a protective effect (SHR 0.52, 95%CI 0.31-0.88; p=0.015), while high tumor grade (grade II: SHR 3.65, 95%CI 1.98-6.72; p<0.001) was associated with an increased risk. Multimodal treatments influenced recurrence patterns but did not independently predict outcomes after adjustment. CONCLUSIONS: Tumor stage, location, and histology were strong predictors of disease-free survival after surgery for esophageal cancer. Histological subtypes significantly influenced recurrence patterns. Squamous cell carcinoma was associated with a higher risk of locoregional recurrence but a lower risk of distant metastasis compared to adenocarcinoma. Multimodal therapy demonstrated a protective effect in stage III disease.	esophagus
Robotic Oesophageal Spindle Cell Lipoma Excision.	Oesophageal lipoma is a benign oesophageal tumour accounting for less than 1% of all the gastrointestinal lipomas. The spindle cell variant of oesophageal lipoma is an even rarer entity. Histologically it is characterized by the presence of varying amounts of mature fat, uniform spindle cells and collagen. To the best of our knowledge, only two cases of spindle cell lipoma (SCL) of the oesophagus have been reported so far. Herein, we present a case of a 52-year-old lady who was evaluated for dysphagia. Oesophago-gastroscopy showed a submucosal mass on the posterolateral wall of the oesophagus on the right side arising at 18-20 cm from incisors. Biopsy was suggestive of squamous hyperplasia with no evidence of dysplasia or malignancy. On computerized tomography (CT) scan of the chest, the mass measured 11.2x3.2x3.3 cm and was seen to extend from the post-cricoid to the infra-carinal region. In view of the major intrathoracic extent, she underwent robotic trans-thoracic excision of the oesophageal lesion. The final histopathology report confirmed SCL of the oesophagus. Immunohistochemical examination was positive for CD 34 and negative for desmin and MDM2. Complete excision of the lesion remains the standard treatment. It is essential to establish a precise diagnosis of SCL of the oesophagus and rule out malignancy.	esophagus
Surgical Outcomes for Cervical Esophageal Cancer: A Retrospective Cohort Study.	BACKGROUND: Although definitive chemoradiotherapy (dCRT) remains the standard for cervical esophageal cancer (CEC), studies on surgical outcomes have reported conflicting results. This highlights the need for more data on surgical treatment for CEC. METHODS: This study reviewed 152 patients who underwent surgical treatment for CEC at a single center between May 2014 and May 2024. Patients were stratified by surgical procedure: laryngeal-preserving esophagectomy (LP) versus. total pharyngo-laryngo-esophagectomy (TPLE). Baseline data and perioperative outcomes were analyzed. Kaplan-Meier analysis and multivariable Cox regression were performed. RESULTS: Eighty-five patients underwent LP whereas 67 patients underwent TPLE. The median follow-up time was 24 months. Overall survival (OS) rate at 2-year for all patients was 58.9%, and a higher 2-year OS rate (71.2% vs. 43.5% and p = 0.035) was observed in the LP group compared to the TPLE group. The TPLE group had a higher R0 resection (negative resection margin) rate (75.3% vs. 89.6% and p = 0.024) but higher incidence of noncancer-related mortality (16.4% vs. 4.7% and p < 0.001) and 90-day mortality (7.5% vs. 0% and p = 0.010) compared to the LP group. Multivariable Cox regression analysis demonstrated that TPLE as an independent risk factor for OS (hazard ratio (HR), 1.872; 95% confidence interval [CI], 1.101-3.184; and p = 0.021). CONCLUSIONS: The survival outcomes of surgical treatment for CEC showed promising when compared to historical data of definitive chemoradiotherapy. Although the LP group had a lower R0 resection rate than the TPLE group, it demonstrated better survival rates and perioperative safety.	esophagus